Paper of the month: Endocrine Therapy in HEGR2 neg mBC


A review that summarized the available data on endocrine therapy for premenopausal women with HER2-negative hormone receptor-positive metastatic breast cancer (MBC) has been published in the Oncologist.

During the past 30 years, the incidence of metastatic breast cancer (MBC) in women aged 25-39 years has slightly increased. Up to date, no comprehensive review exists for therapeutic approaches in that patient population. Therefore, this review aimed to provide clinicians with an overview on the available data regarding endocrine treatment of hormone receptor-positive MBC in premenopausal women and to indicate potential future directions of research.

Tancredi R, Furlanetto J, Loibl S. Endocrine Therapy in Premenopausal Hormone Receptor Positive/Human Epidermal Growth Receptor 2 Negative Metastatic Breast Cancer: Between Guidelines and Literature. Oncologist. 2018; 23:974-981.

Link in PubMed

The Oncologist


GBG Forschungs GmbH
Martin-Behaim-Str. 12 | 63263 Neu-Isenburg | Fax +49 6102 7480-440

+49 6102 7480-0 | nfGBGd